Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9d37ca22e316cf6c70ddaedb9ee233bd http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b0f0829722fbcf55a08941b20816ddcb http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fa5d97928d5c303b11f7bb2aeb6377ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4bde71fe403355b84199c67767a74c64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed75be032a58aef5b16f15a4b379d682 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6876 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-02 |
filingDate |
2010-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2014-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_012909ef3e6c1226335e308ca760a9c2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f6ce774615af4229cedaf2e350e8031 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d90203ed98d5eba8f5e1dfce5b7c7365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e42d2811b0ad01d3478b9adcb714ad46 |
publicationDate |
2014-08-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-8809297-B2 |
titleOfInvention |
Anticancer composition |
abstract |
Disclosed is an anticancer composition, comprising an inhibitor against WIG1 and/or YPEL5 or against a protein encoded by the gene. A composition for screening an anticancer agent comprising a nucleic acid having a sequence complementary to an mRNA of WIG1 and/or YPEL5, or an antibody to a protein encoded by the gene is also provided. Also, a method is provided for screening an anticancer agent, which comprises: (A) quantitatively analyzing expression of WIG1 and/or YPEL5 at an mRNA or protein level in a tumor cell which is not treated with a candidate for an anticancer agent; (B) quantitatively analyzing expression of the gene at an mRNA or protein level in a tumor cell after treatment of the candidate for an anticancer agent; and (C) selecting the candidate if the expression level of the gene is increased in step (B), compared to step (A). |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9550995-B2 |
priorityDate |
2010-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |